A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients

Viatris

Status and phase: Completed; Phase 3

Conditions: Schizophrenia

Treatments: Drug: Ziprasidone; Drug: Risperidone

Study type: Interventional

Funder types: Industry

Identifiers

NCT00645372

A1281115

Details and patient eligibility

About

The purpose of this study is to compare the efficacy and safety of ziprasidone and risperidone for the treatment of schizophrenia in Chinese patients

Enrollment: 242 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hospitalized patients with schizophrenia
• Miminum PANSS score of 60 when randomized

Exclusion criteria

• Planned, regular use of antipsyhotics within 1 week of randomization
• Previous treatment with risperidone that resulted in intolerance or lack of response to risperidone

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

242 participants in 2 patient groups

A

Active Comparator group

Treatment:

Drug: Risperidone

B

Experimental group

Treatment:

Drug: Ziprasidone